Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05896423 · ClinicalTrials.gov registry record
Increasing PrEP Awareness and Demand Among Black Cisgender Women
A clinical trial, sponsored by Northwestern University.
- Completed
- Registry status
- 30
- Enrollment target
NCT05896423: Completed study, sponsored by Northwestern University.
NCT05896423 is a clinical trial that has completed, run by Northwestern University. The registered enrollment target is 30 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05896423 has completed, sponsored by Northwestern University.
- COMPLETED
- Registry status
- 30 participants
- Enrollment target
Study Summary
This study will develop HIV pre-exposure prophylaxis (PrEP) awareness materials for and with Black cis women and gather feedback on the usefulness of these materials at health care sites. The investigators will also use electronic medical records (EMR) to compare the number of Black cis women who initiate PrEP before and after the awareness materials are piloted, at the two partner research sites, Howard Brown Health and Planned Parenthood of IL. Additional federally qualified health centers and family planning clinics will review the materials and complete a survey on acceptability.
Primary Outcome
Number of Black cis women at each clinic with first prescription for any form of HIV PrEP
Interventions
- BEHAVIORAL PrEP awareness materials
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2023-08-15 |
| Est. Completion | 2024-03-31 |
What the finished NCT05896423 record still lists
NCT05896423 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 30 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which PrEP awareness materials is the first listed.
NCT05896423 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05896423 about?
NCT05896423 is a clinical study titled "Increasing PrEP Awareness and Demand Among Black Cisgender Women". This study will develop HIV pre-exposure prophylaxis (PrEP) awareness materials for and with Black cis women and gather feedback on the usefulness of these materials at health care sites. The investigators will also use electronic medical records (EMR) to compare the number of Black cis women who in...
What is the current status of trial NCT05896423?
This trial is currently completed. The enrollment target is 30 participants. The study started on 2023-08-15. Estimated completion is 2024-03-31.
What interventions are being tested in trial NCT05896423?
The interventions under investigation include: PrEP awareness materials (BEHAVIORAL).
Who is sponsoring clinical trial NCT05896423?
This trial is sponsored by Northwestern University, which has 1,209 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI